Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lenny Dang

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Blood|June 8, 2010
MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphomaMichael A Milhollen, Tary Traore, Jennifer Adams-Duffy, et al.
Cancer Cell|August 19, 2007
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myelomaChristina M Annunziata, R Eric Davis, Yulia Demchenko, et al.
The Journal of Clinical Investigation|April 6, 2021
The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse modelAlessandro Matte, Enrica Federti, Charles Kung, et al.
Blood|August 2, 2017
AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiencyCharles Kung, Jeff Hixon, Penelope A Kosinski, et al.
Blood Cells, Molecules & Diseases|April 2, 2022
Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse modelZenaide M N Quezado, Sayuri Kamimura, Meghann Smith, et al.
Nature|November 26, 2009
Cancer-associated IDH1 mutations produce 2-hydroxyglutarateLenny Dang, David W White, Stefan Gross, et al.
Journal of Medicinal Chemistry|April 8, 2021
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous <i>MTAP</i> DeletionZenon Konteatis, Jeremy Travins, Stefan Gross, et al.
ACS Medicinal Chemistry Letters|February 20, 2020
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of GliomaZenon Konteatis, Erin Artin, Brandon Nicolay, et al.
Cancer Cell|January 15, 2021
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA DamagePeter Kalev, Marc L Hyer, Stefan Gross, et al.
Science (New York, N.Y.)|April 6, 2013
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiationFang Wang, Jeremy Travins, Byron DeLaBarre, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Blood|June 8, 2010
MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphomaMichael A Milhollen, Tary Traore, Jennifer Adams-Duffy, et al.
Cancer Cell|August 19, 2007
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myelomaChristina M Annunziata, R Eric Davis, Yulia Demchenko, et al.
The Journal of Clinical Investigation|April 6, 2021
The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse modelAlessandro Matte, Enrica Federti, Charles Kung, et al.
Blood|August 2, 2017
AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiencyCharles Kung, Jeff Hixon, Penelope A Kosinski, et al.
Blood Cells, Molecules & Diseases|April 2, 2022
Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse modelZenaide M N Quezado, Sayuri Kamimura, Meghann Smith, et al.
Nature|November 26, 2009
Cancer-associated IDH1 mutations produce 2-hydroxyglutarateLenny Dang, David W White, Stefan Gross, et al.
Journal of Medicinal Chemistry|April 8, 2021
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous <i>MTAP</i> DeletionZenon Konteatis, Jeremy Travins, Stefan Gross, et al.
ACS Medicinal Chemistry Letters|February 20, 2020
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of GliomaZenon Konteatis, Erin Artin, Brandon Nicolay, et al.
Cancer Cell|January 15, 2021
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA DamagePeter Kalev, Marc L Hyer, Stefan Gross, et al.
Science (New York, N.Y.)|April 6, 2013
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiationFang Wang, Jeremy Travins, Byron DeLaBarre, et al.
Pageof 4